Program
SKB445
A development code. Also written as “SKB445 for injection”.
Its studies are led by Sichuan Kelun Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Kelun Pharmaceutical | 11 open or running | phase 1since Jan 19, 2025 | Jan 19, 2025 | Dec 31, 2026phase 1 · NCT06826040 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 19, 2025First study: phase 1 study in Advanced Solid TumorsFirst studyNCT06826040 · 126 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Advanced Solid TumorsNCT06826040
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06826040Advanced Solid Tumors · China | 1 | Recruiting | Dec 31, 2026 | 126 |
How it is read
Names in the registry
- “SKB445 for injection”, 1 entry
Codes read as this program: SKB445.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.